{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:43:18Z","timestamp":1762004598713},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.diagmicrobio.2014.07.005","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T01:45:28Z","timestamp":1406166328000},"page":"233-238","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)"],"prefix":"10.1016","volume":"80","author":[{"given":"Robert K.","family":"Flamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11318430-000000000-00000","article-title":"Current challenges in antimicrobial chemotherapy: focus on ss-lactamase inhibition","volume":"70","author":"Bebrone","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkh358","article-title":"In vitro activity of AVE1330A, an innovative broad-spectrum non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"54","author":"Bonnefoy","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0015","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.01896-13","article-title":"Contemporary diversity of \u03b2-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent \u03b2-lactamase groups","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0020","series-title":"M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0025","series-title":"M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes: a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0035","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1128\/AAC.00851-12","article-title":"Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa","volume":"56","author":"Crandon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.01198-10","article-title":"Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0050","doi-asserted-by":"crossref","DOI":"10.1179\/1973947813Y.0000000145","article-title":"Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value","author":"Flamm","year":"2013","journal-title":"J Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrurol.2010.190","article-title":"The epidemiology of urinary tract infection","volume":"7","author":"Foxman","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0060","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/650482","article-title":"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America","volume":"50","author":"Hooton","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0070","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1128\/AAC.01722-10","article-title":"Activity of NXL104 in combination with \u03b2-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum b-lactamases and class C b-lactamases","volume":"55","author":"Lagace-Wiens","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0075","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.06064-11","article-title":"In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates","volume":"56","author":"Levasseur","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0080","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0085","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM198209093071101","article-title":"Mortality associated with nosocomial urinary-tract infection","volume":"307","author":"Platt","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0095","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In vitro activity of the \u03b2-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases","volume":"64","author":"Stachyra","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0105","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1128\/AAC.00568-10","article-title":"Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-b-lactam b-lactamase inhibitor","volume":"54","author":"Stachyra","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0110","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diagmicrobio.2014.07.005_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889314002879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889314002879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T11:25:43Z","timestamp":1538393143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889314002879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0732889314002879"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.07.005","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}